

# NEEDLE TIPS

from the Immunization Action Coalition — [www.immunize.org](http://www.immunize.org)

## What's In This Issue

What's New? ACIP Influenza Recommendations for 2016–17 .....	1
Ask the Experts: CDC Answers Your Questions .....	1
Vaccine Highlights: Recommendations, Schedules, and More .....	5
Influenza Vaccine Products for 2016–17 .....	7
Screening Checklist for Contraindications to Influenza Vaccines .....	8
Standing Orders Templates for Influenza Vaccines .....	9
Standing Orders Template for Pneumococcal Vaccines .....	10
How to Administer Influenza Vaccines .....	11
First Do No Harm: Mandatory HCP Influenza Vaccination Policies .....	12
Influenza Education Materials from IAC .....	13
VISs Available in Many Languages .....	14
Give MCV4 #2: Resources for Your Practice .....	15
Products Available for Purchase from IAC .....	16
IAC's Updated Book! Hepatitis B: <i>What Hospitals Need to Do to Protect Newborns</i> .....	17
IAC's Immunization Resources Order Form .....	18



### FEDERAL AND MILITARY EMPLOYEES

Make the Immunization Action Coalition your charity of choice for the Combined Federal Campaign.

Use agency code **#10612**

The Immunization Action Coalition is a 501 (c) (3) charitable organization and your contribution is tax-deductible to the fullest extent of the law.

### Immunization questions?

- ▶ Email [nipinfo@cdc.gov](mailto:nipinfo@cdc.gov)
- ▶ Call your state health department (phone numbers at [www.immunize.org/coordinators](http://www.immunize.org/coordinators))

## What's New in the Influenza Vaccination Recommendations for the 2016–17 Season

On August 26, CDC's Advisory Committee on Immunization Practices (ACIP) recommendations for influenza vaccination for the 2016–17 season were published in *Morbidity and Mortality Weekly Report, Recommendations and Reports*, Vol 65, No.5, available at [www.cdc.gov/mmwr/volumes/65/rr/pdfs/r6505.pdf](http://www.cdc.gov/mmwr/volumes/65/rr/pdfs/r6505.pdf).

ACIP continues to recommend routine annual influenza vaccination for all persons 6 months of age and older who do not have a contraindication for vaccination.

Two important new recommendations were made for the 2016–17 season.

■ **Live attenuated influenza vaccine (LAIV, FluMist, AstraZeneca) is not recommended to be used in any setting during the 2016–17 influenza season.** This recommendation was made because of evidence of low vaccine effectiveness among children 2 through 17 years of age against the H1N1 strain of influenza virus during the 2013–14 and 2015–16 seasons. Only inactivated or recombinant influenza vaccines should be used during the 2016–17 influenza season.

■ **A history of egg allergy is no longer considered to be a contraindication or precaution to influenza vaccination.** Multiple studies have found

that severe allergic reactions to egg-based influenza vaccines in persons with egg allergy are unlikely. For the 2016–17 influenza season, ACIP recommends that people with a history of egg allergy who have experienced only hives after exposure to egg should receive any inactivated influenza vaccine without specific precautions (except for the recommended 15-minute observation period for syncope for any vaccine). People who report having had an anaphylactic reaction to egg may also receive any age-appropriate influenza vaccine. For individuals who have an anaphylactic reaction to eggs that is more than hives, the vaccine should be administered in a medical setting such as a hospital, clinic, health department, or physician office. Vaccine administration should be supervised by a healthcare provider who is able to recognize and manage severe allergic conditions. More information on influenza vaccination and egg allergy is available from the Immunization Action Coalition (IAC) as a staff education sheet titled "Influenza Vaccination of People with a History of Egg Allergy" at [www.immunize.org/catg.d/p3094.pdf](http://www.immunize.org/catg.d/p3094.pdf). ♦

## Ask the Experts

*The Immunization Action Coalition extends thanks to our experts, medical officer Andrew T. Kroger, MD, MPH, and nurse educator Donna L. Weaver, RN, MN, both with the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention (CDC).*

### Influenza vaccines

**Which influenza vaccines will be available during the 2016–17 influenza season?**

Multiple manufacturers are producing influenza vaccine for the U.S. market for the 2016–17 season. Inactivated and recombinant (inactivated) vaccines will be produced using egg-based, cell culture-based, and recombinant technologies. Some of the inactivated influenza vaccines will be quadrivalent (contain four strains of influenza virus) rather than trivalent (three strains). Live attenuated influenza vaccine (LAIV, FluMist, AstraZeneca) is expected

to be available but is not recommended to be used during the 2016–17 season (see next question). A complete listing of influenza vaccine products is available from the Immunization Action Coalition (IAC) at [www.immunize.org/catg.d/p4072.pdf](http://www.immunize.org/catg.d/p4072.pdf).

**Why did CDC's Advisory Committee on Immunization Practices (ACIP) recommend that LAIV not be used during the 2016–17 season?**

This recommendation was made because of evidence of low vaccine effectiveness among children 2 through 17 years of age against the H1N1 strain of influenza virus during the 2013–14 and 2015–16 seasons. The reason for this lack of effectiveness of LAIV is not known. Only inactivated or recombinant influenza vaccines should be used during the upcoming influenza season. Details about this recommendation are available on pages 14–17 of the 2016–17 ACIP influenza recommendations online at [www.cdc.gov/mmwr/volumes/65/rr/pdfs/r6505.pdf](http://www.cdc.gov/mmwr/volumes/65/rr/pdfs/r6505.pdf).

**With the ACIP recommendation to not use LAIV during the 2016–17 season, will there be**

*Ask the Experts...continued on page 2 ▶*

## Needle Tips

online at [www.immunize.org/nt](http://www.immunize.org/nt)  
**Immunization Action Coalition**

2550 University Ave. W., Suite 415 North  
Saint Paul, MN 55114  
Phone: (651) 647-9009  
Email: [admin@immunize.org](mailto:admin@immunize.org)  
Websites: [www.immunize.org](http://www.immunize.org)  
[www.vaccineinformation.org](http://www.vaccineinformation.org)  
[www.immunizationcoalitions.org](http://www.immunizationcoalitions.org)  
[www.give2mcv4.org](http://www.give2mcv4.org)

*Needle Tips* is a publication of the Immunization Action Coalition (IAC) for healthcare professionals. Content is reviewed by the Centers for Disease Control and Prevention (CDC) for technical accuracy. This publication is supported in part by CDC Grant No. 6NH23IP922550. Content is solely the responsibility of IAC and does not necessarily represent the official views of CDC. ISSN 1526-1816.

### Publication Staff

Editor: Deborah L. Wexler, MD  
Associate Editors: William L. Atkinson, MD, MPH; Diane C. Peterson  
Consulting Editors: Teresa Anderson, DDS, MPH; Marian Deegan, JD

### IAC Staff

Chief Strategy Officer:  
L.J. (Litjen) Tan, MS, PhD  
Associate Director for Research:  
Sharon G. Humiston, MD, MPH  
Coordinator for Public Health:  
Laurel Wood, MPA  
Nurse Consultant: Pat Vranesich, RN, BSN  
Coordinator for Hepatitis B Projects:  
Lynn Pollock, RN, MSN  
Perinatal Hepatitis B Consultant:  
Beth Rowe-West, BSN  
Policy Consultant: Sarah R. Landry, MA  
Senior Admin. for Grants and Leadership:  
Julie Murphy, MA  
Senior Project Manager: Robin VanOss  
Operations Manager: Casey Pauly  
Project Administrator: Chrystal Mann

IAC publishes a free email news service (*IAC Express*) and two free periodicals (*Needle Tips* and *Vaccinate Adults*). To subscribe, go to [www.immunize.org/subscribe](http://www.immunize.org/subscribe).

IAC, a 501(c)(3) charitable organization, publishes practical immunization information for healthcare professionals to help increase immunization rates and prevent disease.

### The Immunization Action Coalition is also supported by

Pfizer Inc., Merck Sharp & Dohme Corp., GlaxoSmithKline, Sanofi Pasteur, AstraZeneca, Seqirus, Physicians' Alliance of America, Besse Medical, American Pharmacists Association, Mark and Muriel Wexler Foundation, Herbert and Jeanne Mayer Foundation, and many other generous donors.

IAC maintains strict editorial independence in its publications.

### IAC Board of Directors

Stephanie L. Jakim, MD  
*Olmsted Medical Center*  
Sheila M. Specker, MD  
*University of Minnesota*  
Debra A. Strodthoff, MD  
*Amery Regional Medical Center*  
Deborah L. Wexler, MD  
*Immunization Action Coalition*

## Ask the Experts...continued from page 1

### enough inactivated influenza vaccine (IIV) to meet the demand for the upcoming season?

Influenza vaccine manufacturers project that as many as 157–168 million doses of IIV will be available for the 2016–17 season. Based on these projections, health officials expect that supply of IIV for the 2016–17 season should be sufficient to meet any increase in demand resulting from the ACIP recommendations, though providers may need to check vaccine availability with more than one supplier or purchase a vaccine brand in addition to the one they normally select.

### I know that LAIV is not recommended to be used this season. If a dose of LAIV is administered this season, is it a valid dose, or should we repeat it with IIV?

The dose can be counted. It does not need to be repeated with IIV.

### Please tell me about Fluvad, the new influenza vaccine for people age 65 years and older.

In November 2015, the Food and Drug Administration (FDA) licensed Fluvad (Seqirus), a trivalent, MF59-adjuvanted inactivated influenza vaccine, for people age 65 years and older. Fluvad is the first adjuvanted influenza vaccine marketed in the U.S. An adjuvant is a substance added to a vaccine to increase its immunogenicity. The MF59 adjuvant is based on squalene, an oil that occurs naturally in many plants and animals. Fluvad has been used in Europe since 1997 and is approved in 38 other countries. In contrast to Fluzone High-Dose (Sanofi Pasteur), Fluvad is a standard-dose vaccine, containing 15 mcg of hemagglutinin per dose.

In clinical studies, Fluvad was more effective than standard-dose unadjuvanted vaccine in preventing laboratory-confirmed influenza in elderly people. Fluvad recipients reported more local reactions, such as injection site pain (25% versus 12%) and tenderness (21% versus 11%), than were reported by recipients of an unadjuvanted IIV.

### Who is recommended to receive vaccination against influenza?

ACIP recommends annual vaccination for all people age 6 months and older who do not have a contraindication to the vaccine.

### When should influenza vaccine be administered?

You can begin administering vaccine as soon as it becomes available. Early vaccination of children

younger than age 9 years who need 2 doses can be helpful in assuring routine second doses are given before the influenza season begins.

### We have noticed that ACIP recommends that we begin vaccinating with seasonal influenza vaccine in September or even earlier. Does protection from seasonal influenza vaccine decline or wane within 3 or 4 months of vaccination? Should I wait until later in the year to vaccinate my elderly or medically frail patients?

ACIP recommends that to avoid missed opportunities for vaccination, providers should offer vaccination during routine healthcare visits and hospitalizations as soon as vaccine becomes available. Antibody to inactivated influenza vaccine declines in the months following vaccination. A study conducted during the 2011–12 influenza season (*Euro Surveill* 2013;18:20388) found a decline in vaccine effectiveness late in influenza season, primarily affecting persons age 65 years and older. While delaying vaccination might permit greater immunity later in the season, deferral could result in missed opportunities to vaccinate, as well as difficulties in vaccinating a large number of people within a more limited time period. Vaccination programs should balance maximizing the likelihood of persistence of vaccine-induced protection through the season with avoiding missed opportunities to vaccinate or vaccinating after influenza virus circulation begins. Revaccination later in the season of people who have already been fully vaccinated is not recommended.

### Some of my patients refuse influenza vaccination because they insist they "got the flu" after receiving the injectable vaccine in the past. What can I tell them?

There are several reasons why this misconception persists:

- Less than 1% of people who are vaccinated with the injectable vaccine develop flu-like symptoms, such as mild fever and muscle aches, after vaccination. These side effects are not the same as having influenza, but people confuse the symptoms.
- Protective immunity doesn't develop until 1–2 weeks after vaccination. Some people who get vaccinated later in the season (December or later) may be infected with influenza virus shortly afterward. These late vaccinees develop influenza because they were exposed to someone with the virus before they became immune. It is not the result of the vaccination.

Ask the Experts...continued on page 3 ►

Subscribe to *IAC Express*, the Immunization Action Coalition's e-news and information service at [www.immunize.org/subscribe](http://www.immunize.org/subscribe)

DISCLAIMER: *Needle Tips* is available to all readers free of charge. Some of the information in this issue is supplied to us by the Centers for Disease Control and Prevention in Atlanta, Georgia, and some information is supplied by third-party sources. The Immunization Action Coalition (IAC) has used its best efforts to accurately publish all of this information, but IAC cannot guarantee that the original information as supplied by others is correct or complete, or that it has been accurately published. Some of the information in this issue is created or compiled by IAC. All of the information in this issue is of a time-critical nature, and we cannot guarantee that some of the information is not now outdated, inaccurate, or incomplete. IAC cannot guarantee that reliance on the information in this issue will cause no injury. Before you rely on the information in this issue, you should first independently verify its current accuracy and completeness. IAC is not licensed to practice medicine or pharmacology, and the providing of the information in this issue does not constitute such practice. Any claim against IAC must be submitted to binding arbitration under the auspices of the American Arbitration Association in Saint Paul, Minnesota.

## IAC's "Ask the Experts" team from the Centers for Disease Control and Prevention



Andrew T. Kroger, MD, MPH



Donna L. Weaver, RN, MN

### Ask the Experts...continued from page 2

- To many people "the flu" is any illness with fever and cold symptoms or gastrointestinal symptoms. If they get any viral illness, they may blame it on the vaccine or think they got "the flu" despite being vaccinated. Influenza vaccine only protects against certain influenza viruses, not all viruses.
- The influenza vaccine is not 100% effective, especially in older persons. For more information on this topic, go to [www.cdc.gov/flu/professionals/vaccination/effectivenessqa.htm](http://www.cdc.gov/flu/professionals/vaccination/effectivenessqa.htm).

### Is a Vaccine Information Statement (VIS) only recommended or is it mandatory when administering influenza vaccine?

The use of a VIS for influenza vaccine given to any child or adult is mandatory under the National Vaccine Injury Compensation Program. Two VISs are available, one for LAIV (although LAIV is not recommended to be used during the 2016–2017 season) and one for IIV. Each can be found at [www.immunize.org/vis](http://www.immunize.org/vis) along with many translations. Beginning in the 2015–16 influenza season, the influenza VIS was modified so that it does not need to be replaced each year. The 2015–16 VIS can be used during the 2016–17 season.

### We are trying to provide influenza vaccination to all eligible patients during their stay in our hospital. If a patient does not remember if he or she has already received the vaccine this season, should we go ahead and vaccinate?

If a patient or family member cannot remember if the patient received influenza vaccine this season and no record is available, proceed with administering influenza vaccine, even if it might mean an extra dose is given. When a patient reports that they HAVE received influenza vaccine but does not have written documentation, ACIP states that in the specific case of influenza (and pneumococcal polysaccharide) vaccination, patient self-report of being vaccinated should be accepted as evidence of vaccination.

### Which children younger than age 9 years will need 2 doses of influenza vaccine in this influenza season?

Children age 6 months through 8 years should receive

a second dose 4 weeks or more after the first dose if they 1) are receiving influenza vaccine for the first time, or 2) did not receive a total of at least two doses of trivalent or quadrivalent influenza vaccine before July 1, 2016, or 3) if the child's vaccination history is unknown. The two doses need not have been received during the same season or consecutive seasons.

For more details about the ACIP recommendations for which children need two doses, see [www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6505.pdf](http://www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6505.pdf), page 28.

You can also find this information in IAC's handout titled "Guide for Determining the Number of Doses of Influenza Vaccine to Give to Children Ages 6 Months Through 8 Years." It is available at [www.immunize.org/catg.d/p3093.pdf](http://www.immunize.org/catg.d/p3093.pdf).

### When determining whether a child age 2 through 8 years needs one or two doses of influenza vaccine this season, can we count doses of LAIV administered in past years? We were not sure because LAIV is not recommended this year.

Doses of LAIV administered in past seasons can be counted.

### If a child receives influenza vaccine at age 34 or 35 months for the first time (0.25 mL dose) and then returns for the second dose at age 37 months, should we give another 0.25 mL dose or should we give the 0.5 mL dose that is indicated for ages 3 and older?

The child should always receive the dose appropriate for his or her age at the time of the clinic visit; at age 37 months that would be 0.5 mL.

### What is the latest ACIP guidance on influenza vaccination and egg allergy?

ACIP revised its guidance on vaccination of persons with egg allergy for the 2016–17 season. ACIP recommends that people with a history of egg allergy who have experienced only hives after exposure to egg should receive any inactivated influenza vaccine without specific precautions (except a 15-minute observation period for syncope). People who report having had an anaphylactic reaction to egg (more severe than hives) may also receive any age-appropriate influenza vaccine. The vaccine for those individuals should be administered in a medical setting (such as a health department or physician office). Vaccine administration should be supervised by a healthcare provider who

Ask the Experts...continued on page 4 ►

### Stay current with FREE subscriptions

The Immunization Action Coalition's 2 periodicals, *Needle Tips* and *Vaccinate Adults*, and our email news service, *IAC Express*, are packed with up-to-date information.

Subscribe to all 3 free publications in one place. It's simple! Go to

[www.immunize.org/subscribe](http://www.immunize.org/subscribe)

## Advisory Board

### Liaisons from Organizations

**Bernadette A. Albanese, MD, MPH**  
Council of State & Territorial Epidemiologists

**Stephen L. Cochi, MD, MPH**  
Nat'l Ctr. for Immun. & Resp. Diseases, CDC

**Bruce Gellin, MD, MPH**  
National Vaccine Program Office, DHHS

**Neal A. Halsey, MD**  
Institute for Vaccine Safety, Johns Hopkins Univ.

**Claire Hannan, MPH**  
Association of Immunization Managers

**Carol E. Hayes, CNM, MN, MPH**  
American College of Nurse-Midwives

**Gregory James, DO, MPH, FACOFP**  
American Osteopathic Association

**Samuel L. Katz, MD**  
Pediatric Infectious Diseases Society

**Elyse Olshen Kharbanda, MD, MPH**  
Society for Adolescent Health and Medicine

**Marie-Michele Leger, MPH, PA-C**  
American Academy of Physician Assistants

**Kimberly Martin**  
Assn. of State & Territorial Health Officials

**Lisa M. McKeown, MPH**  
Nat'l Assn. of County & City Health Officials

**Kathleen M. Neuzil, MD, MPH**  
American College of Physicians

**Paul A. Offit, MD**  
Vaccine Education Ctr., Children's Hosp. of Phila.

**Walter A. Orenstein, MD**  
Emory Vaccine Center, Emory University

**Mitchel C. Rothholz, RPh, MBA**  
American Pharmacists Association

**Thomas N. Saari, MD**  
American Academy of Pediatrics

**Margot L. Savoy, MD, MPH**  
American Academy of Family Physicians

**William Schaffner, MD**  
Infectious Diseases Society of America

**Anne Schuchat, MD**  
Centers for Disease Control and Prevention

**Rhoda Sperling, MD**  
Amer. College of Obstetricians & Gynecologists

**Thomas E. Stenvig, RN, PhD**  
American Nurses Association

**Ann S. Taub, MA, CPNP**  
National Assn. of Pediatric Nurse Practitioners

**John W. Ward, MD**  
Division of Viral Hepatitis, NCHHSTP, CDC

**Patricia N. Whitley-Williams, MD, MPH**  
National Medical Association

**Walter W. Williams, MD, MPH**  
Nat'l Ctr. for Immun. & Resp. Diseases, CDC

### Individuals

**Hie-Won L. Hann, MD**  
Jefferson Medical College, Philadelphia

**Mark A. Kane, MD, MPH**  
Seattle, Washington

**Edgar K. Marcuse, MD, MPH**  
University of Washington School of Medicine

**Harold S. Margolis, MD**  
Taos, New Mexico

**Brian J. McMahon, MD**  
Alaska Native Medical Center, Anchorage

**Stanley A. Plotkin, MD**  
Vaxconsult.com

**Gregory A. Poland, MD**  
Mayo Clinic

**Sarah Jane Schwarzenberg, MD**  
University of Minnesota

**Coleman I. Smith, MD**  
Minnesota Gastroenterology, Minneapolis

**Richard K. Zimmerman, MD, MPH**  
University of Pittsburgh

## Ask the Experts...continued from page 3

is able to recognize and manage severe allergic conditions. Although not specifically recommended by ACIP, providers may prefer an egg-free recombinant vaccine (RIV) for people age 18 years and older with severe egg allergy (see next question).

A previous severe allergic reaction to influenza vaccine, regardless of the component suspected to be responsible for the reaction, is a contraindication to future receipt of the vaccine. For a complete list of vaccine components (i.e., excipients and culture media) used in the production of the vaccine, check the package insert (at [www.immunize.org/fda](http://www.immunize.org/fda)) or go to [www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf](http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf).

For more details about giving influenza vaccine to people with a history of egg allergy, see [www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6505.pdf](http://www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6505.pdf), pages 29–30. You also may find the IAC handout “Influenza Vaccination of People with a History of Egg Allergy” helpful (see [www.immunize.org/catg.d/p3094.pdf](http://www.immunize.org/catg.d/p3094.pdf)).

**Does the ACIP prefer that healthcare personnel administer high-dose or adjuvanted influenza vaccine to people age 65 years and older, or is standard-dose influenza vaccine acceptable?**

ACIP has no preference. CDC stresses that vaccination is the first and most important step in protecting against influenza.

**Some of our patients believe that they have had reactions to influenza vaccine in the past, and request the dose to be split into 2 doses administered on different days. Is this an acceptable practice?**

This is definitely not an acceptable practice. Doses of influenza vaccine (or any other vaccine) should

never be split into “half doses.” If a “half dose” is given, it should not be accepted as a valid dose and should be repeated as soon as possible with an age-appropriate full dose.

**The pneumococcal conjugate vaccine (PCV13, Prevnar, Pfizer) package insert says that in adults, antibody responses to PCV13 were diminished when given with inactivated influenza vaccine. Does this mean we should not give PCV13 and influenza vaccine at the same visit?**

The available data have been interpreted that any changes in antibody response to either of the vaccines’ components were clinically insignificant. If PCV13 and influenza vaccine are both indicated and recommended, they should be administered at the same visit. See the PCV13 ACIP recommendations at [www.cdc.gov/mmwr/pdf/wk/mm6337.pdf](http://www.cdc.gov/mmwr/pdf/wk/mm6337.pdf), page 824.

**We inadvertently administered a 0.5 mL dose of Fluvirin (IIV3, Seqirus) to a 2-year-old before realizing that the vaccine is only licensed for use in people age 4 years and**

**older. Do we need to repeat the dose with an age-appropriate product?**

No, the dose does not need to be repeated. However, this is a vaccine administration error as this formulation is not recommended for children younger than age 4 years. Clinicians should carefully select an influenza vaccine that is licensed for the age group of the person being vaccinated. At the time of this writing, Fluzone 0.25 mL (Sanofi Pasteur) is the only inactivated influenza vaccine approved for use in children age 6 months through 35 months of age.

If the child should need a second dose of influenza vaccine, an age-appropriate vaccine should be selected. IAC’s educational piece “Influenza Vaccine Products for the 2016–2017 Influenza Season” (available at [www.immunize.org/catg.d/p4072.pdf](http://www.immunize.org/catg.d/p4072.pdf)) provides helpful information on the wide variety of influenza vaccines in use this season.

**How should influenza vaccines (IIV and LAIV) be stored?**

Both IIV and LAIV should be refrigerated at temperatures between 2°C (36°F) and 8°C (46°F). ♦

### To submit an “Ask the Experts” question...

You can email your questions about immunization to us at [admin@immunize.org](mailto:admin@immunize.org). IAC will respond to your inquiry. Because we receive hundreds of emails each month, we cannot guarantee that we will use your question in “Ask the Experts.” IAC works with CDC to compile new Q&As for our publications based on commonly asked questions. Most of the questions are thus a composite of several inquiries.

### Needle Tips correction policy

If you find an error, please notify us immediately by sending an email message to [admin@immunize.org](mailto:admin@immunize.org). We publish notification of significant errors in our email announcement service, *IAC Express*. Be sure you’re signed up for this service. To subscribe, visit [www.immunize.org/subscribe](http://www.immunize.org/subscribe).

# Ask the Experts



## About IAC’s Question of the Week

Each week, *IAC Express* highlights a new, topical, or important-to-reiterate Q&A. This feature is a cooperative venture between IAC and CDC. William L. Atkinson, MD, MPH, IAC’s associate director for immunization education, chooses a new Q&A to feature every week from a set of Q&As prepared by experts at CDC’s National Center for Immunization and Respiratory Diseases.

To find more than **1,000** Ask the Experts Q&As answered by CDC experts, visit [www.immunize.org/askexperts](http://www.immunize.org/askexperts)

Please encourage your healthcare professional colleagues to sign up to receive *IAC Express* at [www.immunize.org/subscribe](http://www.immunize.org/subscribe).

